The last decade has registered the emerging of novel therapeutic targets in advanced GC, including Programmed Cell Death 1 (PD-1) and HER2, and the subsequent introduction of immunotherapy and HER2 inhibitors in clinical practice following the results of landmark clinical trials in this setting [4,5,6]. This evidence concerns the gene PDCD1 and gastric cancer.